Exogenous nucleotides may improve sleep quality in older adults
In a randomized controlled trial of 122 adults aged 60-70, nearly half of participants had room for improvement in sleep quality at baseline. The study will evaluate changes in sleep quality from baseline to 4 months as part of a comprehensive geriatric health assessment, but results are not yet reported.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Exogenous nucleotides may improve sleep quality in older adults The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Exogenous nucleotides may improve sleep quality in older adults
This conclusion is most relevant to: Community-dwelling older adults aged 60-70 years, predominantly female (67.21%), with pre-frailty and at least one chronic condition.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults. (Nutrients, 2024) —
How It Works
The proposed biological pathway:
- ▸Nucleotides are involved in cellular processes
- ▸May influence aging-related pathways
- ▸Could improve sleep via anti-aging effects
- ▸Result: potential improvement in sleep quality
Who Might Benefit
Evidence fit by population:
- ▸Community-dwelling older adults aged 60-70 years, predominantly female (67.21%), with pre-frailty and at least one chronic condition
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Results are not yet reported; only baseline characteristics are available
- ▸Sleep quality was a secondary outcome, not the primary focus
- ▸Dosage of nucleotides not specified in abstract
Frequently Asked Questions
What is the TALENTs trial?▼
TALENTs is a randomized, double-blinded, placebo-controlled trial evaluating exogenous nucleotides as an anti-aging supplement in adults aged 60-70.
How was sleep quality measured in this study?▼
Sleep quality was assessed as part of a comprehensive geriatric health assessment, but specific instruments are not detailed in the abstract.
What were the baseline sleep characteristics of participants?▼
Nearly half of participants had room for improvement in sleep quality at baseline, though mean scores for related measures were within normal range.
Is there evidence that nucleotides improve sleep?▼
This trial aims to test that, but results are not yet available; the abstract only reports baseline data.
References
- 1.Wang S, Song L, Fan R, Chen Q, You M, Cai M, Wu Y, Li Y, Xu M. “Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults..” Nutrients, 2024. PMID: 38732590 DOI: 10.3390/nu16091343